Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests LASMAR score to improve fibroid surgery planning

NCT ID NCT07578246

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the LASMAR scoring system can predict how well hysteroscopic myomectomy works for women with submucous fibroids. Researchers will check if the score matches surgery time, number of sessions, fluid use, and complications. The goal is to help doctors plan better and reduce risks for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hysteroscopic myomectomy (surgical procedure)
What this could lead to
If successful, this could help doctors better predict surgery time, number of sessions needed, and risks for women with uterine fibroids.
What could go wrong
This is a small, early-stage observational study with only 88 participants, so results may not apply to everyone. The LASMAR score may not accurately predict outcomes in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women undergoing hysteroscopic myomectomy for symptomatic uterine fibroids.

Ages

18 to 45 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-45 years * Type 0,1,2 Fibroids according to Figo classification. * Symptomatic submucous fibroids: Symptoms include abnormal uterine bleeding, pelvic pain or pressure symptoms, infertility or recurrent pregnancy loss. * Fibroids size ≤ 5 cm in diameter * Confirmed diagnosis of leiomyoma by ultrasound . * Hemodynamically Stable Patients: Patients with no significant anemia. Exclusion Criteria: * Contraindications to hysteroscopy (e.g., Pregnancy, pyometra, active infection) * Individuals with significant comorbidities (e.g., severe cardiovascular or respiratory diseases, bleeding diathesis). * Cases requiring concurrent procedures (e.g., Laparoscopic surgeries). * Fibroid Size\>5 cm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lazmar scoring , hysteroscopic myomectomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.